Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board
Dr. David Erritzoe to provide guidance on psychopharmacological research
Vancouver, British Columbia–(August 25, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research, has been appointed to Entheon’s Advisory Board.
Who we are
Entheon is in a unique position to challenge the narrative – and expectations – around addiction recovery.
Leveraging emerging bio-technology, we are pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorder. Focusing primarily on the powerful DMT molecule, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Learn More About Entheon
Investors
